RAPID: Rapid-Acting ParkInson's Drug The Parkinson Study Group (PSG), under the sponsorship of Teva Clinical Research, has conducted a study for advanced Parkinson's disease patients with motor complications ("on-off" effects). This 20-24 week study of TV-1203/Carbidopa dispersible tablets, a novel investigational variation of levodopa, examined the efficacy, safety, and tolerability of TV-1203/Carbidopa dispersible tablets in treating advanced Parkinson disease patients who had motor fluctuations while being treated with chronic levodopa/carbidopa therapy. Teva Clinical Research, based in North Wales, PA is the U.S. affiliate of Teva Pharmaceutical Industries, LTD, Israel, an international pharmaceutical company headquartered in Israel.
This study enrolled approximately 300 patients at 41 sites across the United States and Canada. For more details, contact one of the participating PSG centers nearest you.
...Enrollment for the RAPID study has been completed...
State, City
Site Name
Coordinators Name Phone Number AL, Birmingham University of Alabama at Birmingham Susan Rolli 205-975-8509 AZ, Phoenix Barrow Neurological Institute Derek Sebade 602-406-4758 AZ, Scottsdale Mayo Clinic Scottsdale Marlene Lind 480-301-7644 CA, Fountain Valley Parkinson's & Movement Disorder Institute Nancy Luong 714-378-5074 CA, Los Angeles University of Southern California Cheryl Armstrong 323-442-5723 CA, San Francisco University of California San Francisco Hazel Outlaw 415-750-4180 ext.177 CANADA, Calgary Alberta University of Calgary Medical Lorelei Derwent 403-220-8413 CANADA, Edmonton Alberta University of Alberta Germaine McInnes 780-474-8853 CANADA, London Ontario London Health Sciences Centre Andrew Johnson 519-685-8300 ext. 32307 CANADA, Ottawa Ontario Ottawa Hospital Civic Campus Neila Mendis 613-737-4440 CANADA, Saskatoon Saskatchewan University of Saskatchewan Marianne Ewanishin 306-966-8029 CANADA, Sherbrooke, Quebec University of Sherbrooke Daniel Soucy 819-564-5238 CANADA, Verdun Quebec McGill Center for Studies in Aging Jean Hall 514-766-2010 CO, Englewood Colorado Neurological Institute Deborah Judd 303-762-6667 CT, Farmington University of Connecticut Sheila Belber 860-679-4637 CT, New Haven Institute for Neurodegenerative Disorders Karen Stavris 203 401-4336 FL, Miami Univ. of Miami School of Medicine Anita Blenke 305-243-2572 FL, Tampa University of South Florida Pat Dyches 813-844-4453 IL, Chicago Rush University Medical Center Jeana Jaglin 312-563-2900 IN, Indianapolis Indiana University JoAnn Belden 317-278-0868 KS, Kansas City University of Kansas Medical Center Stephanie Thomas 913-588-6921 MA, Boston Beth Israel Deaconess Med. Center Lisa Scollins 617-667-9885 MA, Boston Boston University Cathi Thomas 617-638-7737 MA, Boston Massachusetts General Hospital Marsha Tennis 617-726-1610 MD, Baltimore Johns Hopkins University Becky Dunlop 410-955-8795 MD, Baltimore University of Maryland Carol Dignon 410-706-2328 MN, Minneapolis University of Minnesota/Hennepin County Medical Center Susan Rolandelli 612-624-8431 MO, St. Louis Washington Univ. School of Medicine Lori McGee-Minnich 314-362-7148 NE, Omaha Creighton University Carolyn Peterson 402-280-4693 NJ, New Brunswick UMDNJ Robert Wood Johnson Med. Ctr. Debbie Caputo 732-235-7945 NY, Albany Albany Medical Center Sharon Evans 518-452-0914 NY, Manhasset North Shore University Hospital Barbara Shannon 516-869-0372 NY, New Hyde Park Long Island Jewish Medical Center Maria Marotta-Kollarus 718-470-7074 NY, New York Beth Israel Medical Center Karyn Boyar 212-844-6134 NY, New York Columbia University Reina Benabou 212-305-2928 NY, Rochester University of Rochester Cheryl Deeley 585-341-7500 OH, Cincinnati University Neurology, Inc. Donna Schwieterman 513-558-4447 OH, Toledo Medical College of Ohio Kathy Davis 419-383-3548 PA, Philadelphia University of Pennsylvania Heather Mulholland 215-829-7181 PR, San Juan Univ. of Puerto Rico School of Med. Laritza Berrios 787-759-0306 ext 235 TN, Memphis University of Tennessee-Memphis Brenda Pfeiffer 901-448-6195
Updated: February 2003